A Whole Virus Pandemic Influenza H1N1 Vaccine Is Highly Immunogenic and Protective in Active Immunization and Passive Protection Mouse Models

The recent emergence and rapid spread of a novel swine-derived H1N1 influenza virus has resulted in the first influenza pandemic of this century. Monovalent vaccines have undergone preclinical and clinical development prior to initiation of mass immunization campaigns. We have carried out a series of immunogenicity and protection studies following active immunization of mice, which indicate that a whole virus, nonadjuvanted vaccine is immunogenic at low doses and protects against live virus challenge. The immunogenicity in this model was comparable to that of a whole virus H5N1 vaccine, which had previously been demonstrated to induce high levels of seroprotection in clinical studies. The efficacy of the H1N1 pandemic vaccine in protecting against live virus challenge was also seen to be equivalent to that of the H5N1 vaccine. The protective efficacy of the H1N1 vaccine was also confirmed using a severe combined immunodeficient (SCID) mouse model. It was demonstrated that mouse and guinea pig immune sera elicited following active H1N1 vaccination resulted in 100% protection of SCID mice following passive transfer of immune sera and lethal challenge. The immune responses to a whole virus pandemic H1N1 and a split seasonal H1N1 vaccine were also compared in this study. It was demonstrated that the whole virus vaccine induced a balanced Th-1 and Th-2 response in mice, whereas the split vaccine induced mainly a Th-2 response and only minimal levels of Th-1 responses. These data supported the initiation of clinical studies with the same low doses of whole virus vaccine that had previously been demonstrated to be immunogenic in clinical studies with a whole virus H5N1 vaccine.

[1]  R. Gasparini,et al.  Impact of prior or concomitant seasonal influenza vaccination on MF59‐adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects , 2010, International journal of clinical practice.

[2]  J. Devaster,et al.  Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. , 2010, Vaccine.

[3]  N. Halasa.  Update on the 2009 pandemic influenza A H1N1 in children , 2010, Current opinion in pediatrics.

[4]  A. Arguedas,et al.  Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. , 2010, The New England journal of medicine.

[5]  J. McVernon,et al.  Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. , 2010, JAMA.

[6]  Xiaofeng Liang,et al.  Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial , 2010, The Lancet.

[7]  Z. Vajo,et al.  Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial , 2010, The Lancet.

[8]  M. Blatter,et al.  Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials , 2010, The Lancet.

[9]  A. Osterhaus,et al.  Animal models for the preclinical evaluation of candidate influenza vaccines , 2010, Expert review of vaccines.

[10]  K. Hoschler,et al.  Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.

[11]  X. Zhang,et al.  A novel influenza A (H1N1) vaccine in various age groups. , 2009, The New England journal of medicine.

[12]  C. Wichems,et al.  Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.

[13]  A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. , 2009, The Journal of infectious diseases.

[14]  R. Rappuoli,et al.  Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice , 2009, PLoS currents.

[15]  Hideo Goto,et al.  In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses , 2009, Nature.

[16]  Marion Koopmans,et al.  Pathogenesis and Transmission of Swine-Origin 2009 A(H1N1) Influenza Virus in Ferrets , 2009, Science.

[17]  Rahul Raman,et al.  Transmission and Pathogenesis of Swine-Origin 2009 A(H1N1) Influenza Viruses in Ferrets and Mice , 2009, Science.

[18]  Hong Sun,et al.  Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. , 2009 .

[19]  T. Popović,et al.  Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. , 2009, MMWR. Morbidity and mortality weekly report.

[20]  S. Rewar,et al.  Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[21]  H. Ehrlich,et al.  A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. , 2008, The New England journal of medicine.

[22]  M. Howard,et al.  Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines , 2008, Biological chemistry.

[23]  F. Falkner,et al.  Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. , 2007, Vaccine.

[24]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[25]  R. Ahmed,et al.  Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral Replication , 2001, Journal of Virology.

[26]  M Kundi,et al.  One-hit models for virus inactivation studies. , 1999, Antiviral research.

[27]  F. Dorner,et al.  Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. , 1998, Vaccine.

[28]  K. Mozdzanowska,et al.  Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice , 1995, Journal of virology.

[29]  P. Scherle,et al.  Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. , 1992, Journal of immunology.

[30]  V. Seagroatt,et al.  Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. , 1979, Journal of biological standardization.

[31]  V. Seagroatt,et al.  An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. , 1977, Journal of biological standardization.

[32]  A. S. Beare,et al.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.